Profound Medical Corp (PROF) Stock Price, Quote & News

Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or phys...

Industry: Medical Devices

Sector: Healthcare

Phone: 647 476 1350

Fax: 647 847 3739

Website: www.profoundmedical.com

Address:

2400 Skymark Avenue, Unit 6, Mississauga, Canada

Bmdubb Jan. 23 at 9:58 PM

$PROF adding dips into the 7s

0 · Reply

BioTuesdays Jan. 15 at 1:55 PM

$PROF has announced that the world-renowned Mount Sinai Hospital, Metro New York (NYC), has successfully treated its first prostate cancer patient with the TULSA-PRO system https://biotuesdays.com/2026/01/15/mount-sinai-becomes-first-in-nyc-to-deliver-incision-free-mri-guided-prostate-treatment-with-profounds-tulsa-pro/

0 · Reply

BioTuesdays Jan. 12 at 4:45 PM

$PROF announced that its TULSA-PRO system installed base reached 78 as of December 31, 2025—exceeding its previously announced goal of 75 installs by year-end 2025 https://biotuesdays.com/2026/01/12/profound-surpasses-2025-tulsa-pro-installed-base-goal/

0 · Reply

QES Jan. 12 at 4:44 PM

$PROF TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ...is pleased to announce that its TULSA-PRO® system installed base stood at 78 as of December 31, 2025 — higher than its previously announced goal of 75 installs by the end of 2025. Profound’s TULSA-PRO qualified sales pipeline also grew to 97 new systems being classified within one of the “Verify, Negotiate and Contracting” stages at year-end. “As the installed base grows, we expect that it will lead to higher patient treatment rates and, correspondingly, continued growth of our high margin recurring revenue,” said Profound’s CEO and Chairman, Arun Menawat. “That is being driven primarily by the TULSA Procedure’s ability to treat an unrivaled range of prostate diseases, severities, and aggressions, while preserving crucial functions like continence and sexual health of the patient. We look forward to releasing our fourth quarter and full year 2025 financial results near the end of February 2026.”

0 · Reply

QES Jan. 6 at 2:02 PM

$PROF "Seeing Hopkins put TULSA-PRO into a purpose-built iMRI OR and treat non‑trial patients addresses concerns about workflow, safety, and reputational risk, making it easier for other institutions and larger clinics to justify capital spend and program launch."

0 · Reply

BioTuesdays Jan. 6 at 1:00 PM

Johns Hopkins Medicine treats first commercial TULSA-PRO case; Profound marks major milestone as hospital launches iMRI suite to expand access to advanced prostate care $PROF https://biotuesdays.com/2026/01/06/johns-hopkins-medicine-treats-first-commercial-tulsa-pro-case-profound-marks-major-milestone-as-hospital-launches-imri-suite-to-expand-access-to-advanced-prostate-care/

0 · Reply

NetworkNewsWire Dec. 31 at 2:29 PM

InvestorNewsBreaks – $PROF; $PRN.TO Closes $36 Million Registered Direct Offering https://ibn.fm/oqsae

0 · Reply

SuperGreenToday Dec. 19 at 3:55 PM

$PROF Share Price: $7.70 Contract Selected: Jul 17, 2026 $5 Calls Buy Zone: $1.91 – $2.36 Target Zone: $3.47 – $4.24 Potential Upside: 71% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Stock_Catcher Dec. 19 at 1:45 PM

$PROF Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

0 · Reply

Doozio Dec. 19 at 12:51 AM

Prolly still need moar chop chop but da 🧠 shud still spread on the $DLO $PROF wUtch out for that margin exposure on da FRYday close. Bullish engulf da week $DAVE 🐒🍌🧠⏰♾️

1 · Reply

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

Dec 30, 2025, 4:30 PM EST - 4 weeks ago

Profound Medical Corp. Announces Closing of Private Placement

Dec 24, 2025, 1:15 PM EST - 5 weeks ago

Profound Medical Corp. Announces Upsize of Private Placement

Dec 23, 2025, 8:00 AM EST - 6 weeks ago

Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

Dec 19, 2025, 8:45 AM EST - 6 weeks ago

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

Dec 4, 2025, 5:00 PM EST - 2 months ago

Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation

Nov 28, 2025, 7:45 AM EST - 2 months ago

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

Nov 18, 2025, 4:15 PM EST - 2 months ago

Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease

Nov 13, 2025, 10:11 PM EST - 2 months ago

Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript

PRN

Nov 13, 2025, 4:05 PM EST - 2 months ago

Profound Medical Reports Strong Third Quarter 2025 Financial Results

Nov 12, 2025, 8:30 AM EST - 2 months ago

Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

Nov 11, 2025, 4:15 PM EST - 2 months ago

Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia

Oct 14, 2025, 8:30 AM EDT - 4 months ago

Profound Medical to Participate in the Stifel 2025 Healthcare Conference

Oct 7, 2025, 7:45 AM EDT - 4 months ago

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Sep 23, 2025, 8:00 AM EDT - 4 months ago

Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment

Aug 28, 2025, 8:00 AM EDT - 5 months ago

Profound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth Conference

Aug 18, 2025, 7:01 PM EDT - 6 months ago

Profound Medical: Smokes Is Everywhere, Initiate At Sell

Aug 14, 2025, 9:24 PM EDT - 6 months ago

Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript

PRN

Aug 14, 2025, 4:05 PM EDT - 6 months ago

Profound Medical Announces Second Quarter 2025 Financial Results

Jul 24, 2025, 5:00 PM EDT - 6 months ago

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

May 14, 2025, 4:45 PM EDT - 9 months ago

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

May 9, 2025, 7:17 AM EDT - 9 months ago

Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript

Apr 30, 2025, 4:30 PM EDT - 9 months ago

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 29, 2025, 7:30 AM EDT - 10 months ago

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Apr 15, 2025, 7:45 AM EDT - 10 months ago

Profound Medical AUA 2025 Investor Event Agenda

Apr 8, 2025, 10:00 AM EDT - 10 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 8, 2025, 9:32 AM EDT - 10 months ago

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

Apr 7, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

Apr 6, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

Apr 4, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

Apr 3, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

Apr 2, 2025, 10:00 AM EDT - 10 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

Mar 31, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

Mar 28, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

Mar 27, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

Mar 26, 2025, 9:59 PM EDT - 11 months ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws

Mar 26, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

Mar 25, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

Mar 24, 2025, 1:00 PM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

Mar 6, 2025, 8:35 PM EST - 11 months ago

Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript

Feb 13, 2025, 5:00 PM EST - 1 year ago

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Jan 8, 2025, 7:30 AM EST - 1 year ago

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Jan 6, 2025, 8:15 AM EST - 1 year ago

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 9:55 AM EST - 1 year ago

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Dec 6, 2024, 9:04 AM EST - 1 year ago

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Bmdubb Jan. 23 at 9:58 PM

$PROF adding dips into the 7s

0 · Reply

BioTuesdays Jan. 15 at 1:55 PM

0 · Reply

BioTuesdays Jan. 12 at 4:45 PM

0 · Reply

QES Jan. 12 at 4:44 PM

0 · Reply

QES Jan. 6 at 2:02 PM

0 · Reply

BioTuesdays Jan. 6 at 1:00 PM

0 · Reply

NetworkNewsWire Dec. 31 at 2:29 PM

InvestorNewsBreaks – $PROF; $PRN.TO Closes $36 Million Registered Direct Offering https://ibn.fm/oqsae

0 · Reply

SuperGreenToday Dec. 19 at 3:55 PM

0 · Reply

Stock_Catcher Dec. 19 at 1:45 PM

$PROF Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

0 · Reply

Doozio Dec. 19 at 12:51 AM

Prolly still need moar chop chop but da 🧠 shud still spread on the $DLO $PROF wUtch out for that margin exposure on da FRYday close. Bullish engulf da week $DAVE 🐒🍌🧠⏰♾️

1 · Reply

Doozio Dec. 16 at 2:37 AM

Things that make YO go hmmm $PROF 🐒🍌🧠⏰⏰

1 · Reply

Doozio Dec. 10 at 11:54 PM

$IWM cmon $PROF They said the real pullback comes after $MAMA reaches the east side n all da bums are bullish. Could be eating 💯 🍔s with that $LMND as IWM retests this $$$$ pattern ENTA 🐒🍌🧠⏰♾️

1 · Reply

Doozio Dec. 6 at 5:24 PM

$ZETA chop chop huckleberries $PROF 🐒🍌🧠⏰♾️

0 · Reply

Doozio Dec. 6 at 3:00 PM

chop chop huckleberries ENTA 🐒🍌🧠⏰♾️ $PROF

0 · Reply

RunnerSignals Dec. 6 at 8:35 AM

Hot Stocks to Watch 🔥 $HRTG $BNTC $PROF Big moves alert! Heritage Benitec and Profound are on fire with huge upside potential https://stocksrunner.com/news/2025-12-06-short-term-stocks-with-analyst-upgrades-and-strong-upside-potential

0 · Reply

BioTuesdays Dec. 5 at 3:55 PM

$PROF has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the Cum Laude award for his presentation titled “CAPTAIN Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation (TULSA) Versus Robotic Radical Prostatectomy” at the 2025 Radiological Society of North America (RSNA) Annual Meeting, yesterday in Chicago https://biotuesdays.com/2025/12/05/stanfords-dr-ghanouni-receives-cum-laude-award-for-rsna-presentation-on-captain-trial-of-tulsa-v-robotic-radical-prostatectomy/

1 · Reply

QES Nov. 28 at 3:03 PM

$PROF https://finance.yahoo.com/news/profound-medical-launch-ai-powered-124500774.html This new BPH module is yet another major selling point for the TULSA Pro system. It comes less than 6 months after the first commercial BPH procedure. "On the company’s own math, BPH and hybrid BPH/cancer patients would expand the eligible pool by about 2× relative to the prostate-cancer-focused base, taking total from 1× to about 3×, i.e., BPH roughly doubles the market on top of what cancer alone provides. That does not automatically translate to revenue tripling (penetration, ASPs, and mix matter), but from an addressable-procedure standpoint, BPH is positioned by management as the main lever to move from a ~200k-case world to a ~600k-case world."

1 · Reply

johntarlick Nov. 21 at 1:54 PM

$PROF some interesting patterns in the institutional holdings for Q3. Longtime holders Letko and Timelo took substantial reductions of about 20%, even as RayJames has virtually exited their position altogether. On the plus side, Royce increased their position. Gagnon's stayed on the sidelines despite the very attractive prices recently. RayJames had been an inveterate booster of this stock for years dating back to former analyst Rahul Sarugaser, and just two months ago issued an "OUTPERFORM" targeting $11.00. What happened? Am I reading fintel.io wrong?

0 · Reply

johntarlick Nov. 21 at 1:32 PM

$PROF i had thought this stock was on the move at last, following what seemed like a great earnings call, and proving me wrong when i asserted below they'd never get 7.50 on a share offering this year. Then we promptly gave up 15%?? what happened.

0 · Reply

BioTuesdays Nov. 19 at 2:09 AM

$PROF has announced today that The Hong Center Scottsdale, led by Dr. Y. Mark Hong of Integrative Urology in Phoenix, Arizona, has achieved a world-first milestone: 200 TULSA Procedures™ performed independently by a urologist, without radiologist involvement. This landmark establishes a new model for delivering MRI-guided prostate therapy https://biotuesdays.com/2025/11/18/profound-celebrates-the-hong-centers-200th-independent-tulsa-procedure-dr-mark-hong-sees-tulsa-ultimately-replacing-radical-prostatectomy-as-a-first-line-option-for-prostate-cancer/

0 · Reply

healthcareguru Nov. 14 at 4:20 PM

$PROF New BANKRUPTCY risk filed…you were warned. Enjoy the epic dilution which is the VERY NEXT CATALYST. Going <$3 quickly… 🐺👎 $IHI $IWM $XLV $XBI

3 · Reply

jiggs10 Nov. 14 at 3:59 PM

$PROF. Prof and $EDAP should just merge to put up better numbers together n complete more with $ISRG ...

2 · Reply

Market Cap	272.21M
Revenue (ttm)	10.68M
Net Income (ttm)	-27.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-260.49%
Debt to Equity Ratio	0.14

Volume	260,500
Avg Vol	177,596
Day's Range	N/A - N/A
Shares Out	36.29M
Stochastic %K	52%
Beta	0.54
Analysts	Strong Sell
Price Target	$12.56